4月21日 - ** 制药商礼来LLY.N股价下跌2.2%至900美元
** 花旗称，联合健康UNH.N对其加入一项可能扩大礼来Zepbound等GLP-1肥胖症药物覆盖范围的拟议医保计划表示怀疑，礼来因此面临压力。
** CMS的 "BALANCE "计划旨在开放GLP-1减肥药的医保范围，可能从2027年1月开始广泛使用。
** CVS Health CVS.N也表示不会参与该计划，这增加了保险公司接受该计划的不确定性。
** 花旗表示，此番抵制的时机并不令人意外，并将其视为公开谈判而非最终决定
** 包括盘中走势在内，LLY 下跌 16.3%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.